A Skrabl-Baumgartner1, W Erwa2, W Muntean1, J Jahnel1. 1. a Department of Paediatrics and Adolescent Medicine , Medical University Graz , Austria. 2. b Institute of Medical and Chemical Laboratory Diagnostics , Medical University Graz , Austria.
Abstract
OBJECTIVES: We aimed to determine how loss of response (LOR) to adalimumab (ADA) in juvenile idiopathic arthritis (JIA) may be related to anti-ADA antibodies (AAA). METHOD: AAA and ADA levels were measured in 23 consecutive patients with JIA responding significantly to treatment with ADA. RESULTS: Six out of 23 (26%) patients developed AAA and had low ADA levels. Five out of six AAA-positive patients experienced LOR. In these patients use of concomitant methotrexate (MTX) was significantly lower. CONCLUSIONS: The occurrence of AAA is a frequent event associated with LOR. Monitoring of AAA and serum ADA levels should be considered in JIA patients under ADA therapy.
OBJECTIVES: We aimed to determine how loss of response (LOR) to adalimumab (ADA) in juvenile idiopathic arthritis (JIA) may be related to anti-ADA antibodies (AAA). METHOD:AAA and ADA levels were measured in 23 consecutive patients with JIA responding significantly to treatment with ADA. RESULTS: Six out of 23 (26%) patients developed AAA and had low ADA levels. Five out of six AAA-positive patients experienced LOR. In these patients use of concomitant methotrexate (MTX) was significantly lower. CONCLUSIONS: The occurrence of AAA is a frequent event associated with LOR. Monitoring of AAA and serum ADA levels should be considered in JIA patients under ADA therapy.
Authors: B Gorovits; D J Baltrukonis; I Bhattacharya; M A Birchler; D Finco; D Sikkema; M S Vincent; S Lula; L Marshall; T P Hickling Journal: Clin Exp Immunol Date: 2018-03-30 Impact factor: 4.330
Authors: Varvara Choida; Margaret Hall-Craggs; Bethany R Jebson; Corinne Fisher; Maria Leandro; Lucy R Wedderburn; Coziana Ciurtin Journal: Front Pharmacol Date: 2021-02-02 Impact factor: 5.810